Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Other Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Other Non-Current Assets data on record, last reported at $155.5 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 11692.19% to $155.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $155.5 million, a 11692.19% increase, with the full-year FY2025 number at $118.8 million, up 84.66% from a year prior.
  • Other Non-Current Assets reached $155.5 million in Q1 2026 per PCVX's latest filing, up from $118.8 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for PCVX hit a ceiling of $155.5 million in Q1 2026 and a floor of $871000.0 in Q3 2022.
  • A 5-year average of $27.2 million and a median of $1.5 million in 2025 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: plummeted 72.01% in 2024, then surged 11692.19% in 2026.
  • Tracing PCVX's Other Non-Current Assets over 5 years: stood at $871000.0 in 2022, then increased by 26.64% to $1.1 million in 2023, then surged by 5734.9% to $64.4 million in 2024, then soared by 84.66% to $118.8 million in 2025, then skyrocketed by 30.87% to $155.5 million in 2026.
  • Business Quant data shows Other Non-Current Assets for PCVX at $155.5 million in Q1 2026, $118.8 million in Q4 2025, and $1.5 million in Q3 2025.